This review examines beta-glucans as possible vaccine and cancer-immunotherapy adjuvants. It summarizes proposed links between innate and adaptive immune responses, recognition by receptors including Dectin-1, complement receptor 3, CD5, and lactosylceramide, and relationships between glucan structure and biological activity. The article combines research involving beta-glucans from multiple sources and does not report a new clinical trial. It supports further adjuvant research but does not establish that a particular beta-glucan improves vaccine effectiveness or cancer outcomes in people.
A review of beta-glucan receptor recognition, structure-activity relationships, and proposed immunoadjuvant applications.
The reviewed evidence is heterogeneous and does not prove clinical adjuvant efficacy for a specific beta-glucan.
AI-generated summary for accessibility. Always refer to the original paper.
Jin Y., Li P., Wang F.. β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties. Vaccine. 2018. DOI: 10.1016/j.vaccine.2018.07.038.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.